Clinical TrialMay 11, 2026, 09:32 AM
BridgeBio Acoramidis shows 34% reduction in CV hospitalizations vs tafamidis
AI Summary
BridgeBio Pharma announced new Phase 3 ATTRibute-CM study data for acoramidis at Heart Failure 2026, demonstrating consistent and clinically meaningful benefits across the ATTR-CM disease spectrum. New findings showed acoramidis significantly reduced cardiovascular hospitalizations by 34% compared to tafamidis in an indirect comparison, with a favorable 28% hazard reduction in all-cause mortality. The data also highlighted acoramidis' ability to increase sTTR, significantly reduce sTTR variability, and drive early and sustained reductions in outpatient worsening heart failure, reinforcing its differentiated profile.
Key Highlights
- Acoramidis demonstrated a 34% reduction in cardiovascular hospitalizations versus tafamidis.
- Acoramidis showed a favorable 28% hazard reduction in all-cause mortality versus tafamidis.
- Acoramidis reduced the risk of outpatient worsening heart failure versus placebo by 41%.
- Acoramidis significantly reduced sTTR variability versus placebo (9.5% vs 12.8%; p<0.001).
- Reduction in sTTR variability mediated 20% of acoramidis’ treatment effect on mortality.
- Acoramidis consistently blunted the 30-month increase in NT-proBNP by about 50%.